6533b822fe1ef96bd127ce99
RESEARCH PRODUCT
Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19
José Luis PiñanaR. García SanzRodrigo MartinoMaría García RoaGabriel Andrés Martín MartínIrene Risco GálvezRodrigo MartinoMar Tormo DíazPilar Martínez BarrancoPilar Martínez BarrancoSara Marcos CorralesMarisa CalabuigVenancio ConesaAnabel TeruelSara Ruiz PérezCarlos Solano VercetDavid Navarro OrtegaÁNgel CedilloAnna Suredasubject
virusesHematologyVirusdescription
Patients with hematological malignancies have been excluded from the new zoonotic coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) vaccine trials despite being at higher risk for SARS-CoV-2 disease (COVID-19)-related mortality. However, most health authorities worldwide have designated these patients as a priority for COVID-19 vaccination, even in the absence of efficacy data in these highly immunosuppressed patients. In addition, on 12 August 2021, the US Food and Drug Administration amended the emergency use authorizations for the Pfizer-BioNTech and Moderna COVID-19 vaccines to allow for the use of an additional dose in immunocompromised individuals, such as solid organ transplant recipients or equivalently immunosuppressed patients.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2022-01-08 |